Pfizer BioNTech’s COVID-19 booster vaccine has been given backing by the European Union’s drug regulator on Monday for people aged 18 and over. The European Medicines Agency (EMA) sated that the booster doses may be considered at least 6 months after the second dose has been administered for anyone over the age of 18. Following studies which showed a rise in antibody levels following booster doses, the recommendation was issued by the agency’s human medicines committee.
The agency is in support of giving a third dose of either the Pfizer jab or the Moderna vaccine to people with severely weakened immune systems at least 28 days after their second shot. This decision also comes after studies showed a similar increase in antibody production against the COVID-19 virus in people with weekend systems and organ transplant patients. The EMA recommendations go to the European Commission for approval and then to health authorities in all 27 EU nations, who in turn decide the rollout strategy.
Numerous studies have indicated that the Pfizer, and even Moderna, shots remain strongly protective months after people receive second dose. Hospitalisation and death are massively decreased, with the World Health Organisation (WHO) urging wealthy nations not to use booster doses this year as there is no data proving they are necessary. It said that vaccines would be better used in helping developing countries which are still low on even administering their first shots.
Photo Source: The Financial Times